Material Deficiencies in the Dissident’s Gold Proxy Have Been Identified by LabGoldThe Dissident’s Failure to Adhere to its Own Requisition May Affect the Validity of Their Gold ProxyShareholders are Urged to Vote ONLY on the BLUE Proxy or BLUE VIF to Ensure Votes Are Counted, and to Disregard any Gold or Other Proxy That They Receive From the Dissident Questions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit ...

Material Deficiencies in the Dissident’s Gold Proxy Have Been Identified by LabGoldThe Dissident’s Failure to Adhere to its Own Requisition May Affect the Validity of Their Gold ProxyShareholders are Urged to Vote ONLY on the BLUE Proxy or BLUE VIF to Ensure Votes Are Counted, and to Disregard any Gold or Other Proxy That They Receive From the Dissident Questions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit ...

Urges Shareholders to Act Today and Vote ONLY on the BLUE Proxy or VIF to Protect LabGold from a Self-Serving Dissident Who is Attempting to Take Control Without Paying Shareholders a PremiumQuestions? Need Help Voting BLUE? Contact Kingsdale Advisors at 1-888-518-6813 (toll-free in North America), email contactus@kingsdaleadvisors.com, or visit www.TheFutureofLAB.com TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) today announced that ...

Financial Results - Standard BioTools Inc. reported preliminary financial results for the three months and fiscal year ended December 31, 2025, which are unaudited and subject to adjustments[4]. - The financial information provided does not represent a comprehensive statement of the Company's financial results and remains subject to completion of financial closing procedures[4]. Press Release - The press release detailing these results was issued on January 8, 2026, and is attached as Exhibit 99.1[4].

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced it has completed ...

Core Viewpoint - Labrador Gold Corp. is preparing for its Annual General and Special Meeting of Shareholders on February 24, 2026, where key matters including the election of directors and a proposed Change of Business will be discussed [1][2]. Meeting Details - The Meeting Materials include information on the election of LabGold directors, the proposed Change of Business to a Mining/Investment Issuer, and a name change related to the COB [2]. - Shareholders are encouraged to vote in favor of the management's resolutions and against the resolutions proposed by the Dissident, Coloured Ties Capital Inc. [3]. Strategic Direction - The Board is implementing a Change of Business strategy that integrates mining and investment opportunities to enhance liquidity, mitigate risk, and create multiple growth avenues [4]. - A thorough review of 29 resource-stage projects and 22 pre-resource projects over the past 18 months led to the conclusion that a hybrid model is the best approach for shareholder value [5]. Leadership and Expertise - The Corporation's nominees for the Board possess proven expertise in technical, operational, and capital markets, ensuring alignment with shareholder interests [6]. - Dr. Quinton Hennigh has been retained as a technical advisor, emphasizing a disciplined approach to capital deployment [7]. Financial Decisions - The Board has made strategic financial decisions, such as divesting the Kingsway Project to eliminate a $1 million monthly drilling commitment and monetizing shares of New Found Gold Corp. for immediate capital [9]. - These actions have optimized the treasury and positioned the Corporation for long-term growth and value creation [10]. Dissident Concerns - The Dissident, Coloured Ties, has a history of shareholder value destruction and conflicts of interest, raising concerns about their ability to manage the Corporation effectively [11][12]. - The Dissident's nominees lack the qualifications and capabilities necessary to execute the Corporation's strategic plan, with a documented history of poor performance in other ventures [12]. Meeting Participation - The Meeting will be held in person, and shareholders are encouraged to vote as soon as possible, with a voting deadline of February 20, 2026 [14][15].

Core Insights - Standard BioTools Inc. reported preliminary and unaudited revenue results for the full year 2025, expecting combined company revenue of approximately $185 million and revenue from continuing operations of approximately $85 million [1] - The fourth quarter 2025 is projected to have combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million [1] Financial Performance - The CEO of Standard BioTools, Michael Egholm, stated that the company's 2025 performance exceeded guidance and expectations for both combined and continuing operations [2] - The company is on a path toward profitability, having taken actions to streamline operations and improve cost structure, resulting in a leaner organization [2] Strategic Outlook - The sale of SomaLogic to Illumina is expected to close in the first half of 2026, with the company anticipating approximately $550 million in cash post-transaction [2] - The company aims to pursue disciplined mergers and acquisitions to build a diversified leader in life sciences, supported by an experienced team and a simplified operational footprint [2] Company Overview - Standard BioTools Inc. specializes in next-generation technologies that assist biomedical researchers in developing better medicines faster, focusing on areas such as oncology, immunology, and immunotherapy [4]

Core Viewpoint - Labrador Gold Corp. has acquired 16,666,667 Subscription Receipts of Northern Shield Resources Inc. for an investment of $1,000,000.02, pending shareholder and regulatory approval for a change of business model to include equity investments in other resource companies [1][2]. Investment Details - The Subscription Receipts were purchased at a price of $0.06 each, and upon meeting the Escrow Release Conditions, they will convert into Units consisting of one common share and one warrant [1][4]. - Each warrant allows the purchase of an additional common share at a price of $0.10 for 36 months from the Escrow Release Date [1]. Rights and Conditions - As long as Labrador Gold retains a 10% equity interest in Northern Shield, it will have pre-emptive rights for future financings and the right to appoint a technical advisor for exploration activities [2]. - The Units acquired will be subject to a four-month voluntary lockup agreement post-Escrow Release Date [2]. Ownership Structure - Following the financing, Labrador Gold will beneficially own approximately 10.965% of Northern Shield's issued capital on a non-diluted basis and 19.76% on a partially diluted basis, assuming all warrants are exercised [4]. Future Intentions - The company has stated that the Subscription Receipts were acquired for investment purposes, with no current intention to increase or decrease its holdings in Northern Shield, although it may adjust its ownership through various means [5]. Company Background - Labrador Gold is focused on mineral exploration, particularly in acquiring and exploring gold projects in Eastern Canada [9].

Core Viewpoint - Labrador Gold Corp. is transitioning its business model to a hybrid mining/investment issuer to enhance exploration strategies and provide investors with access to undervalued public equities and early-stage opportunities [1][3][4] Business Transition - The company plans to shift from a pure exploration focus to include equity investments in other resource companies, maintaining its exploration activities while seeking to control or manage investee companies [7][9] - The initial investment will involve purchasing $1 million in units of Northern Shield Resources Inc. as part of a subscription receipts financing [7][19] Strategic Rationale - The change is aimed at addressing inefficiencies in capital markets and appealing to investors looking for unique mining investments not currently available in public markets [3][4] - The company intends to leverage its technical and capital markets expertise to guide investee companies towards value creation [3][10] Key Personnel - Dr. Quinton Hennigh, a renowned geologist with 39 years of experience, will join as an investment advisor to assist in sourcing high-quality investment opportunities [5][6] - Kevin Ramsay, CPA, CA, will join the Board of Directors, enhancing the company's governance and financial oversight [1][7] Investment Strategy - The company aims to provide shareholders with access to unique investment opportunities, combining early-stage access with public market investments [11][18] - Initial capital deployment will be $4 million into at least two resource company investments, with plans to raise additional capital to scale the investment model [15][18] Properties Overview - The Hopedale Property will serve as the qualifying property for the change of business, covering 790 mining claims with significant exploration potential for gold and critical metals [27][28] - The Root and Cellar Property, owned by Northern Shield, shows promise for gold and porphyry copper systems, with initial drilling indicating high-grade mineralization [21][22][23] Future Plans - The company will hold an Annual General and Special Meeting on February 24, 2026, to seek shareholder approval for the change of business [1][34] - Following approval, the company will commence trading as a hybrid resource/investment issuer, with a focus on creating long-term shareholder value through strategic investments [34][42]

Core Insights - Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a quiet news cycle [1] Company Summaries - Modular Medical, Inc. (MODD) shares increased by 11.51% to $0.4380 after a previous decline of 1.80% at the close, following the IRB approval for its Pivot insulin delivery system study announced on November 17 [2] - Standard BioTools Inc. (LAB) saw a 4.90% rise to $1.50 after a 0.70% gain during regular trading, following a strategic collaboration with Molecular Instruments announced on November 19 [3] - Werewolf Therapeutics, Inc. (HOWL) rose 4.39% to $1.0199 after a strong 7.33% gain during regular trading, reflecting continued investor optimism despite no new updates [4] - Cogent Biosciences, Inc. (COGT) climbed 6.09% to $42.85 in after-hours trading, building on a 1.69% rise during regular trading, indicating strong investor confidence in its pipeline [5] - Longeveron Inc. (LGVN) shares increased by 4.59% to $0.6772, extending gains from a 7.02% rise during regular trading, with upcoming presentation of Alzheimer's study results at CTAD 2025 highlighting ongoing research [6] - AbCellera Biologics Inc. (ABCL) gained 3.85% to $3.78 after a 0.55% increase during regular trading, reflecting renewed investor interest in its antibody discovery platform [7]